# Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A

> **NCT06802055** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Aplastic Anaemia

## Interventions

- **DRUG:** Sirolimus (Rapamune®)
- **DRUG:** Cyclosporin A (CsA)

## Key facts

- **NCT ID:** NCT06802055
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-25
- **Primary completion:** 2026-01
- **Final completion:** 2027-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06802055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06802055, "Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT06802055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*